Collaboration With Servier on CRC

The core idea of that partnership is that we are identifying novel targets in colorectal cancer. And I would refer listeners back to a previous podcast that I did with David Lee of Servier. Gosh, he talked about France-based company and really making its move into oncology in the US. Both commercially and in research and development. So that was one of those strategic moves that they made. It's going really well. We are seeing new things that other people haven't seen or published on before that could potentially be impactful in CRC.